CACNA1F
Basic information
Region (hg38): X:49205063-49233371
Previous symbols: [ "CSNB2", "AIED" ]
Links
Phenotypes
GenCC
Source:
- congenital stationary night blindness (Supportive), mode of inheritance: AD
- cone-rod dystrophy (Supportive), mode of inheritance: AD
- Aland island eye disease (Supportive), mode of inheritance: XL
- Aland island eye disease (Definitive), mode of inheritance: XL
- congenital stationary night blindness 2A (Strong), mode of inheritance: XL
- X-linked cone-rod dystrophy 3 (Strong), mode of inheritance: XL
- Aland island eye disease (Strong), mode of inheritance: XL
- inherited retinal dystrophy (Definitive), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Aland Island eye disease; Cone-rod dystrophy, X-linked, 3; Night blindness, congenital stationary, X-linked, type 2A | XL | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Ophthalmologic | 14230113; 14213931; 9662400; 9662399; 11381068; 12111638; 12807962; 16505158; 17525176; 20001510; 20301423; 22194652; 22744390 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (67 variants)
- Congenital stationary night blindness 2A (9 variants)
- Congenital stationary night blindness (5 variants)
- Retinal dystrophy (5 variants)
- X-linked cone-rod dystrophy 3 (5 variants)
- CACNA1F-related disorder (3 variants)
- Ocular albinism, type II (3 variants)
- Cone-rod dystrophy (2 variants)
- Congenital stationary night blindness, type 2A, severe (1 variants)
- Myopia;Amblyopia (1 variants)
- Ocular albinism, type II;X-linked cone-rod dystrophy 3;Congenital stationary night blindness 2A (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CACNA1F gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 208 | 227 | |||
missense | 511 | 31 | 11 | 558 | ||
nonsense | 37 | 42 | ||||
start loss | 1 | |||||
frameshift | 29 | 38 | ||||
inframe indel | 10 | 13 | ||||
splice donor/acceptor (+/-2bp) | 32 | 40 | ||||
splice region | 1 | 29 | 38 | 4 | 72 | |
non coding | 121 | 30 | 159 | |||
Total | 76 | 48 | 542 | 361 | 51 |
Highest pathogenic variant AF is 0.0000178
Variants in CACNA1F
This is a list of pathogenic ClinVar variants found in the CACNA1F region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-49205141-A-C | Uncertain significance (Sep 13, 2022) | |||
X-49205145-C-T | Uncertain significance (Jan 27, 2022) | |||
X-49205146-G-A | Likely benign (Jan 14, 2024) | |||
X-49205151-C-T | Uncertain significance (Jul 03, 2023) | |||
X-49205152-G-A | Likely benign (Sep 23, 2022) | |||
X-49205164-G-A | Likely benign (Sep 04, 2021) | |||
X-49205164-G-C | Uncertain significance (Nov 27, 2023) | |||
X-49205175-C-T | Congenital stationary night blindness 2A | Uncertain significance (Jan 04, 2024) | ||
X-49205184-C-G | Uncertain significance (Nov 28, 2022) | |||
X-49205184-C-T | Uncertain significance (Jul 12, 2022) | |||
X-49205189-C-A | Uncertain significance (Apr 20, 2022) | |||
X-49205189-C-T | Uncertain significance (Aug 13, 2022) | |||
X-49205190-G-A | Uncertain significance (Dec 01, 2023) | |||
X-49205191-G-A | Likely benign (Aug 10, 2022) | |||
X-49205192-G-A | Benign (Jun 13, 2023) | |||
X-49205202-A-C | Uncertain significance (Feb 05, 2022) | |||
X-49205208-C-T | Uncertain significance (May 29, 2022) | |||
X-49205209-G-A | not specified | Benign (Jan 29, 2024) | ||
X-49205211-C-G | Uncertain significance (Dec 11, 2023) | |||
X-49205211-C-T | Conflicting classifications of pathogenicity (Dec 22, 2023) | |||
X-49205212-G-A | Likely benign (Jan 18, 2023) | |||
X-49205216-T-G | Uncertain significance (Apr 24, 2021) | |||
X-49205228-G-A | Uncertain significance (Jan 12, 2022) | |||
X-49205231-C-T | Uncertain significance (Dec 15, 2021) | |||
X-49205263-C-A | Uncertain significance (Jun 25, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CACNA1F | protein_coding | protein_coding | ENST00000376265 | 48 | 28311 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000123 | 1.00 | 125712 | 13 | 22 | 125747 | 0.000139 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.60 | 632 | 845 | 0.748 | 0.0000704 | 12869 |
Missense in Polyphen | 128 | 198.73 | 0.64408 | 3093 | ||
Synonymous | 1.60 | 301 | 338 | 0.889 | 0.0000285 | 3980 |
Loss of Function | 5.40 | 23 | 72.7 | 0.316 | 0.00000574 | 1114 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000662 | 0.000528 |
Ashkenazi Jewish | 0.000140 | 0.0000992 |
East Asian | 0.000435 | 0.000326 |
Finnish | 0.0000644 | 0.0000462 |
European (Non-Finnish) | 0.000130 | 0.0000879 |
Middle Eastern | 0.000435 | 0.000326 |
South Asian | 0.000272 | 0.000163 |
Other | 0.000221 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Isoform 1: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long- lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Activates at more negative voltages and does not undergo calcium-dependent inactivation (CDI), due to incoming calcium ions, during depolarization. {ECO:0000269|PubMed:27226626}.; FUNCTION: Isoform 6: Voltage-dependent L-type calcium channel activates at more hyperpolarized voltages and exibits a robust calcium-dependent inactivation (CDI), due to incoming calcium ions, during depolarizations. {ECO:0000269|PubMed:27226626}.;
- Disease
- DISEASE: Night blindness, congenital stationary, 2A (CSNB2A) [MIM:300071]: A non-progressive retinal disorder characterized by impaired night vision, often associated with nystagmus and myopia. {ECO:0000269|PubMed:11281458, ECO:0000269|PubMed:12111638, ECO:0000269|PubMed:12187427, ECO:0000269|PubMed:15897456, ECO:0000269|PubMed:22194652, ECO:0000269|PubMed:9662399, ECO:0000269|PubMed:9662400}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy, X-linked 3 (CORDX3) [MIM:300476]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors. {ECO:0000269|PubMed:16505158}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Aaland island eye disease (AIED) [MIM:300600]: A retinal disease characterized by a combination of fundus hypopigmentation, decreased visual acuity due to foveal hypoplasia, nystagmus, astigmatism, protan color vision defect, myopia, and defective dark adaptation. Except for progression of axial myopia, the disease can be considered to be a stationary condition. Electroretinography reveals abnormalities in both photopic and scotopic functions. {ECO:0000269|PubMed:17525176, ECO:0000269|PubMed:22194652}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Cortisol synthesis and secretion - Homo sapiens (human);Aldosterone synthesis and secretion - Homo sapiens (human);Oxytocin signaling pathway - Homo sapiens (human);Retrograde endocannabinoid signaling - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Serotonergic synapse - Homo sapiens (human);Cardiac muscle contraction - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Dilated cardiomyopathy (DCM) - Homo sapiens (human);Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human);GnRH signaling pathway - Homo sapiens (human);Alzheimer,s disease - Homo sapiens (human);Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human);Adrenergic signaling in cardiomyocytes - Homo sapiens (human);Calcium signaling pathway - Homo sapiens (human);cAMP signaling pathway - Homo sapiens (human);Vascular smooth muscle contraction - Homo sapiens (human);Renin secretion - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);cGMP-PKG signaling pathway - Homo sapiens (human);Cholinergic synapse - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Celecoxib Pathway, Pharmacodynamics;Valproic Acid Pathway, Pharmacodynamics;Pathway_PA165964473;Alzheimers Disease;Arrhythmogenic Right Ventricular Cardiomyopathy;MAPK Signaling Pathway;GPCR Dopamine D1like receptor;Phase 0 - rapid depolarisation;Phase 2 - plateau phase;Cardiac conduction;Muscle contraction
(Consensus)
Recessive Scores
- pRec
- 0.198
Intolerance Scores
- loftool
- 0.0573
- rvis_EVS
- -0.83
- rvis_percentile_EVS
- 11.53
Haploinsufficiency Scores
- pHI
- 0.259
- hipred
- N
- hipred_score
- 0.432
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.690
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cacna1f
- Phenotype
- cellular phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype;
Zebrafish Information Network
- Gene name
- cacna1fa
- Affected structure
- retinal cone cell
- Phenotype tag
- abnormal
- Phenotype quality
- quality
Gene ontology
- Biological process
- calcium ion transport;visual perception;regulation of ion transmembrane transport;T cell homeostasis;regulation of T cell receptor signaling pathway;detection of light stimulus involved in visual perception;calcium ion import;calcium ion transmembrane transport
- Cellular component
- photoreceptor outer segment;plasma membrane;voltage-gated calcium channel complex;integral component of membrane;perikaryon
- Molecular function
- voltage-gated calcium channel activity;high voltage-gated calcium channel activity;metal ion binding